FDA Requires New Clinical Trial Before Considering Summit’s Lung Cancer Drug

Summit stock fell again after the FDA cited insufficient survival data and China-heavy trial enrollment for its lung cancer drug.

FDA Requires New Clinical Trial Before Considering Summit’s Lung Cancer Drug
Photo by CDC on Unsplash
Already have an account? Sign in.